Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
12/01/2026 21:06
Jan 12 (Reuters) - SEC Filing: ACTUATE THERAPEUTICS INC - REPORTS POSITIVE PHASE 2 TRIAL DATA FOR ELRAGLUSIB - SEC FILING ACTUATE THERAPEUTICS INC - PHASE 2 STUDY SHOWS IMPROVED SURVIVAL WITH ELRAGLUSIB - SEC FILING Source text: [ID:n0001683168-26-000217] Further company coverage: ACTU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsActuate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Actuate Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing